Entyvio (vedolizumab) reduces the results of a substance within the body which will cause inflammation.
Entyvio is employed in adults with moderate to severe colitis (UC), or moderate to severe regional ileitis.
Entyvio treats active unwellness and will facilitate keep UC or Crohn’s symptoms in check future. Vedolizumabmight also scale back the requirement for steroid medicines in serving to to manage symptoms future.
Entyvio is typically given when different medicines are tried while not success.
Submit your review
Get emergency medical help if you have any of these signs of an allergic reaction to Entyvio: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Some side effects may occur during the injection. Tell your caregiver right away if you feel warm or tingly, or if you have a severe headache, fast heart rate, pounding in your neck or ears, chest tightness, or trouble breathing.
Some people using a medicine similar to Entyvio have developed a serious viral infection of the brain that can lead to disability or death. Call your doctor right away if you have any change in your mental state, decreased vision, or problems with speech or walking. These symptoms may start gradually and get worse quickly.
Stop using Entyvio and call your doctor at once if you have:
fever, chills, body aches, cold or flu symptoms, mouth and throat ulcers, skin sores;
pain, warmth, swelling, or oozing around your anal area;
nausea, vomiting, severe diarrhea, diarrhea that is watery or bloody, stomach cramps, weight loss;
cough, pain when swallowing; or
liver problems - nausea, upper stomach pain, itching, tired feeling, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes).
Common Entyvio side effects may include:
fever, sore throat, flu symptoms;
cold symptoms such as stuffy nose, sinus pain, sneezing, cough;
pain in your arms or legs;
headache, joint pain, back pain;
rash, itching; or
Usual Adult Dose of Entyvio for Crohn's Disease - Maintenance: Ulcerative colitis and Crohn's disease: 300 mg IV at zero, two and six weeks and then every eight weeks thereafter. Comments: Discontinue if no evidence of therapeutic benefit by Week 14. Uses: Adult Ulcerative Colitis (UC): Adults with moderately to severely active UC who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids. This drug is used for inducing and maintaining clinical response or remission, improving endoscopic appearance of the mucosa, or achieving corticosteroid-free remission. Adult Crohn's Disease(CD): Adults with moderately to severely active CD who have had an inadequate response with, lost response to, or were intolerant to a TNF blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids. This drug is used for achieving clinical response or remission, or achieving corticosteroid-free remission.